April 20, 2004(1)

FOR: ZOLL Medical Corporation

INVESTOR CONTACT: A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832
rminicucci@zoll.com



FOR IMMEDIATE RELEASE

ZOLL MEDICAL SIGNS EXCLUSIVE LICENSE AGREEMENT WITH LIFECOR

CHELMSFORD, MASS  Tuesday, April 20, 2004 – ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices, today announced it has entered into an exclusive license agreement with LIFECOR, Inc. Under this license agreement, ZOLL has acquired all marketing and distribution rights to LIFECOR’s technology for in-hospital use in exchange for $5 million in cash and a return of the $3.5 million equity investment that ZOLL previously maintained in LIFECOR. ZOLL is also providing a working capital line of credit secured by LIFECOR’s accounts receivable and other assets.

The licensed technology includes LIFECOR’s Life•Padz System, which is a next-generation in-hospital wearable cardioverter defibrillator awaiting clearance from the U.S. Food and Drug Administration (FDA). Under the agreement, LIFECOR is obligated to produce product for ZOLL. ZOLL also gains access to, and will continue to use, the LIFECOR and LifeVest™ brands in the hospital market.

In addition, ZOLL also obtained an option, exercisable through October 2005, to purchase the rest of LIFECOR’s assets, including LIFECOR’s out-of-hospital business. If the option is exercised, ZOLL will assume LIFECOR’s debt, not to exceed $6.5 million, and will make earnout payments to LIFECOR’s shareholders, based upon future revenue growth of the acquired business over a five-year period. All elements of the agreement are subject to LIFECOR shareholder approval.

The LifeVest is the world’s only wearable external defibrillator. In 2002, it was approved for use in the U.S. by the FDA through the premarket approval (PMA) process. Commercial distribution began in 2003, and the product is currently being sold by 10 sales representatives in the United States. This technology has been used on over 900 patients. To date, 19 patients wearing a LifeVest have suffered sudden cardiac arrest and been resuscitated successfully. Over 200 doctors have prescribed the LifeVest for their patients. In the out-of-hospital environment, it is being prescribed for those patients that are at high risk of sudden cardiac arrest but are not otherwise protected.

Commenting on the agreement, Richard A. Packer, President and Chief Executive Officer of ZOLL, said, “We have been interested in having wearable defibrillator technology as part of the ZOLL portfolio since our original investment in LIFECOR. We have long seen the potential for a wearable defibrillator to become an integral part of the Chain of Survival in both the out-of-hospital and in-hospital settings.”

For hospitals, the LifeVest offers both clinical and economic advantages. A dedicated wearable device will allow a high-risk patient to receive constant monitoring and an immediate fully automatic lifesaving shock if required. Use will ensure a high standard of care by reducing the time-to-treatment interval for patients needing defibrillation. While fully automated defibrillation has existed, LIFECOR’s wearable cardioverter defibrillator technology brings a new level of mobility to patients. The LifeVest provides both patient and staff the benefit of unhindered patient mobility. Greater mobility can help lower the risks of blood clots and other ailments that can slow recovery. Additionally, the LifeVest offers hospitals the potential cost advantage of being able to move at risk patients out of critical-care beds to lower-cost units while maintaining the fastest response time to a potentially life-threatening arrhythmia.

Mr. Packer added, “While the purchase of LIFECOR’s hospital business is an important step for ZOLL, we look forward to the possibility of obtaining the out-of-hospital business which represents a larger market opportunity. We believe that wearable defibrillator systems may become the standard of care for patients who have a high risk of sudden cardiac arrest for a temporary period. Such patients are currently fitted with an expensive implantable cardioverter defibrillator (ICD) or left unprotected.”

Mr. Packer concluded, “This transaction represents another move to broaden our product offerings in the resuscitation arena. We do not expect a significant impact on our 2004 operating results as a result of this agreement. If the LIFECOR out-of-hospital business ramps up as anticipated and we choose to exercise our option, we will add another potentially significant growth product to ZOLL.”

About LIFECOR
LIFECOR, Inc., based in Pittsburgh, Pa., is a privately owned medical equipment design and manufacturing company that designs, manufactures, and markets the LifeVest wearable external defibrillator system. The company was founded by Dr. M. Stephen Heilman who introduced the world's first implantable cardioverter defibrillator. For more information, visit www.lifecor.com or call 1-800-LIFECOR.

About ZOLL Medical Corporation
ZOLL Medical Corporation (NASDAQ: ZOLL), with worldwide headquarters in Chelmsford, Massachusetts, designs, manufactures, and markets non-invasive cardiac resuscitation solutions. These solutions include pacing and defibrillation devices (ZOLL’s M Series™ and AED Plus™, and LIFECOR, Inc.’s LifeVest™ Wearable Defibrillator), circulatory assist devices (Advanced Circulatory Systems, Inc.’s ResQPOD™ Circulatory Enhancer and Revivant Corporation’s AutoPulse™); and a unique fluid resuscitation product called the Power Infuser®, manufactured by Infusion Dynamics, a division of ZOLL. These devices help health care professionals, emergency medical service providers, and first responders diagnose and treat cardiac arrest wherever it occurs. Through its subsidiary ZOLL Data Systems, ZOLL also designs and markets software that automates the collection and management of both clinical and non-clinical data.

ZOLL has sales operations in Australia, Austria, Canada, China, France, Germany, India, The Netherlands, Russia, the United Kingdom, and the United States, and business partners in all of the world’s major markets. For more information, visit www.zoll.com or call 978-421-9655.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company’s business, our ability to differentiate our products from others on the market, and other statements contained herein regarding matters that are not historical facts, are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled "Risk Factors" in the Company’s Quarterly Report on Form 10-Q filed with the SEC on February 18, 2004.
# # #

Copyright © 2004 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AED Plus and M Series are trademarks of ZOLL Medical Corporation. The LifeVest System is a trademark of LIFECOR, Inc. The ResQPOD is a trademark of Advanced Circulatory Systems, Inc. The AutoPulse Resuscitation System is a trademark of Revivant Corporation. Power Infuser is a registered trademark of Infusion Dynamics. ZOLL is a registered trademark of ZOLL Medical Corporation. All trademarks are property of their respective owners.